Top 10 imugene.com competitors & alternatives
[One moment, please... Imugene is a clinical stage immuno-oncology company developing a range of
new treatments that seek to activate the immune system of cancer patients
to identify and eradicate tumors. ASX: IMU]
imugene.com competitors and alternatives
Top 10 imugene.com competitors and alternatives are ranked by similar search terms, traffic and worth.
imugene.com's top 5 competitors are: imu.com with 0 daily traffic and 11,000 estimated worth, biotechdispatch.com.au with 0 daily traffic and 800 estimated worth, biotechdaily.com.au with 0 daily traffic and 100 estimated worth, volparasolutions.com with 0 daily traffic and 0 estimated worth, imeasureu.com with 0 daily traffic and 0 estimated worth.
volparasolutions.com
Volpara Health | Software to Prevent Advanced-Stage Breast Cancer - Volpara Health
Prevent advanced-stage cancer. Volpara's groundbreaking Breast Health Platform leverages AI for clinical decision support, personalized care and quality management to ignite a revolution in early detection of breast cancer.
Daily Traffic: 0
Website Worth: $ 0
imeasureu.com
IMeasureU - Leading Wearable Sports Sensors For Athlete Performance
IMeasureU provides Wearable Sports Motion Sensors to inform decisions on elite sport health & performance - acurately assess and optimize athlete fitness.
Daily Traffic: 0
Website Worth: $ 0
mimotopes.com
Peptides, Peptide Synthesis, Peptide Library, Custom Peptides
Mimotopes' online peptide superstore provides custom peptide synthesis, peptide library synthesis and peptide reagents for immunology, drug discovery, bioassay development, epitope mapping, proteomics, target discovery and lead optimization.
Daily Traffic: 0
Website Worth: $ 0
nextbiotech.com.au
Next Biotech
Next Biotech is run by a team of experienced industry professionals who have successfully traded and invested in bio tech stocks for many years.
Daily Traffic: 0
Website Worth: $ 0
actinogen.com.au
Home - Actinogen
FOCUSED ON DEVELOPING AN INNOVATIVE TREATMENT FOR COGNITIVE IMPAIRMENT due to raised cortisol ASSOCIATED WITH NEUROLOGICAL DISEASES Ethics Committee approval for XanaMIA StudyActinogen has received approval from the Bellberry Human Research Ethics Committee (HREC) to commence the first part of the XanaMIA study, designed to study improvements in cognitive ability in older volunteers, and patients … Continue reading "Home"
Daily Traffic: 0
Website Worth: $ 0
Share on Social Media
Similar sites like imugene.com